Argenx reported successful Phase 3 clinical trial results for its drug VYVGART Hytrulo, targeting autoimmune myositis, especially benefiting patients with IMNM who lack approved therapies. The trial met its primary endpoint with statistically significant improvement, boosting investor confidence. Analyst Wedbush raised Argenx's price target to $1,150, indicating a potential 16.42% stock upside. This development highlights Argenx's progress in addressing severe autoimmune diseases and could drive future growth.
Morgan Stanley increased its price target for Targa Resources to $343, maintaining an Overweight rating due to the company's strong Q2 results and growth outlook. Targa Resources exceeded profit estimates with a 38% rise in adjusted EBITDA, driven by...
Amer Sports reported strong Q3 results with earnings per share of $0.22, doubling analyst expectations and up from $0.06 last year. Revenue reached $1.63 billion, surpassing the $1.54 billion consensus and showing significant growth from $1.24 billio...
Home Depot reported strong quarterly results with earnings per share of $4.92 and revenue of $47.86 billion, both surpassing analyst expectations. This growth comes amid a 'frozen housing market' where customers prefer smaller maintenance projects du...
Toll Brothers, a luxury homebuilder, is set to report Q3 earnings with an expected EPS of $2.93 and revenue of $2.62 billion, down from last year's $3.73 EPS and $2.95 billion revenue. The decline is mainly due to high mortgage rates reducing demand ...
Okta's stock surged following multiple analyst upgrades from firms like Jefferies, Wells Fargo, Citizens, and KeyBanc, who raised their price targets amid optimism about AI's indirect boost to Okta's identity management business. The company is outpe...
